The HeartCycle Nitrates Study - to assess the effectiveness of non-invasive devices in measuring responses to hydralazine with and without isosorbide mononitrate in heart failure patients

ISRCTN ISRCTN04764631
DOI https://doi.org/10.1186/ISRCTN04764631
Secondary identifying numbers HeartCycle Nitrates Study
Submission date
14/03/2013
Registration date
08/05/2013
Last edited
13/06/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
We intend to investigate how good new non-invasive sensors are at detecting the response of the heart and circulation to single doses of two types of drug that have been in widespread use (nitrates and hydralazine), alone and in combination, for the management of heart failure. The effects of physiological manoeuvres such as standing and leg raising on blood circulation will also be studied. The focus of this study is to assess the ability of non-invasive sensors to detect and track changes in congestion and blood circulation.

Who can participate?
Male and female heart failure patients aged over 18, and a control group of patients with stable coronary artery disease or high blood pressure without heart failure.

What does the study involve?
In the heart failure group, we will investigate the ability of non-invasive sensors to detect changes in congestion and blood circulation in response to changes in two drugs that are recommended for the management of heart failure, although not used routinely. Patients in this group will be studied on four occasions at least 72 hours apart. Each study day lasts up to about eight hours. Patients will be asked to avoid large changes in daily diet in the three days before each study period. On study days patients will be asked to take their usual morning heart failure medications apart from loop diuretics. Patients will be asked to bring their diuretic with them to be given immediately after being weighed. They will then have a 60-minute investigation period using wearable, non-invasive monitoring devices, many of which are already commercially available. Then the following drugs will be administered to the patient in a random order:
1. No extra medication.
2. A tablet of isosorbide mononitrate.
3. A tablet of hydralazine.
4. On the final study day both isosorbide mononitrate and hydralazine, unless the patient had any problems with side effects from these medicines on the previous study days, in which case this study day will be omitted.
The control patients will be studied on a single occasion with their usual daily treatment withheld for 4 hours. Only physiological manoeuvres will be studied and not drug therapy.

What are the possible benefits and risks of participating?
Not provided.

Where is the study run from?
Hull York Medical School, Cottingham, UK.

When is the study starting and how long is it expected to run for?
The study will run from April to September 2013.

Who is funding the study?
European Union 7th Framework Programme (Belgium).

Who is the main contact?
James Illingworth
James.Illingworth@hey.nhs.uk

Contact information

Mr James Illingworth
Scientific

Research and Development Department
Hull University Teaching Hospitals NHS Trust
Office 14, 2nd Floor Daisy Building
Castle Hill Hospital
Cottingham
HU16 5JQ
United Kingdom

Phone +44 (0)1482 461903
Email James.Illingworth@hey.nhs.uk

Study information

Study designOpen label randomised study
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeScreening
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleAssessing the acute haemodynamic effects of hydralazine and nitrates, singly and in combination, in patients with chronic heart failure using novel non-invasive sensor technologies
Study acronymHeartCycle Nitrates Study
Study objectivesThe main study objective is to investigate the ability of a variety of noninvasive sensors to detect changes in haemodynamics (e.g. blood pressure, heart rate, cardiac output, vascular resistance and venous pressure) and congestion induced by hydralazine and isosorbide mononitrate, singly and in combination.
Ethics approval(s)NRES Committee: Yorkshire & The Humber - Leeds West, Approval date: 12 March 2013, Ref: 13/YH/0059
Health condition(s) or problem(s) studiedChronic heart failure
InterventionRandomisation will be by blocks using an unequal block size.

Control group – 10 patients with hypertension or coronary artery disease but not heart failure. The control group does not receive pharmacological therapies.

There other group is the heart failure group (16). Every patient in this group receives all the therapies in a random sequence (unless if there are side effects).

Comparison being made by administering the therapies in random order is to assess the ability of non-invasive sensors to detect and reliably track cardiovascular physiological changes in response to the administered therapy.

The focus of this study is to assess the ability of these devices to detect more subtle changes in congestion and haemodynamics that might be used to guide therapy and thus aid our ability to improve cardiovascular health maintenance rather than just detect and manage crises.

In the heart failure group (16 patients), we will investigate the ability of non-invasive sensors to detect changes in congestion and haemodynamics in response to changes in two vasodilators that are recommended in therapeutic guidelines for the management of heart failure, although not used routinely. Patients in this group will be studied on four occasions at least 72 hours apart. Each study day lasts up to about eight hours. Patients will be asked to avoid large changes in daily diet in the three days before each study period. As part of the consent process, patients will be introduced to the sensors and manoeuvres required in the study. On study days patients will be asked to take their usual morning heart failure medications apart from loop diuretics. Patients will be asked to bring their diuretic with them to be given immediately after being weighed. They will then have a 60 minute investigation period involving the assessment of haemodynamic variables using novel, wearable, non-invasive monitoring devices, many of which are already commercially available and CE marked. These include devices measuring: real-time central venous pressure and cardiac output (Mespere Venus 1000); blood pressure (Nexfin); lung-congestion (Philips BIM); pulse wave velocity (ENVERDIS) and expiratory nitric oxide (INNOCOR).
Then the following pharmacological therapies will be administered to the patient in random order:
1. No extra medication
2. A tablet of isosorbide mononitrate (20mg dose)
3. A tablet of hydralazine (25mg dose)
4. (On the final study day) both isosorbide mononitrate (20mg) and hydralazine (25mg) unless the patient had any problems with side effects from these medicines on the previous study days, in which case this study day will be omitted.

These measurements will be compared to those obtained using physical examination, cardiac ultrasound and plasma concentrations of NT-proBNP.

In addition, 10 control patients with stable coronary artery disease or hypertension without heart failure or gross cardiac dysfunction will be studied on a single occasion with their usual daily treatment withheld for 4 hours. Only physiological manoeuvres will be studied and not pharmacological therapy.

The results will form the basis of a clinical calibration protocol that may become a routine part of home telemonitoring services. The information will also be used to design intelligent algorithms to remotely optimise the patient’s cardiac status.
Intervention typeDevice
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)
Primary outcome measureNo single primary outcome. This is a pilot study to investigate the ability of novel noninvasive sensors to detect and track the acute haemodynamic effects of medication (hydralazine and/or hydralazine or combination) and a series of physiological manoueuvres.
Secondary outcome measuresNo secondary outcome measures
Overall study start date01/04/2013
Completion date20/09/2013

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants26 (16 with heart failure; 10 control patients with stable coronary artery disease or controlled hypertension)
Key inclusion criteria1. Male and female, 18 y.o. plus, legally able to provide written informed consent
2. Clinical diagnosis of Heart Failure
3. Objective evidence of cardiac dysfunction
3.1. NTproBNP >200ng/L and at least one of the following:
3.2. Left ventricular ejection fraction (≤45%)
3.3. Left atrial dimension >40mm
4. Treated with at least 40mg/day of furosemide or 1mg/day of bumetanide
5. Receiving other guideline indicated therapy for heart failure
6. Patients should be in sinus rhythm. Atrial fibrillation may reduce accuracy of some signals
Key exclusion criteria1. Patients with implanted pacemakers or defibrillators
2. Severe aortic or mitral valve disease
3. Breathlessness at rest or on minor exertion
4. Chest pain at rest or on mild or moderate exertion
5. Patients with unstable heart failure or 'brittle' diabetes
6. Patients who are known to be intolerant [including patients using Phosphodiesterase type 5 (PDEV) inhibitors] of nitrates or hydralazine
Date of first enrolment01/04/2013
Date of final enrolment20/09/2013

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Department of Cardiology
Cottingham
HU16 5JQ
United Kingdom

Sponsor information

Hull and East Yorkshire Hospitals NHS Trust (UK)
Hospital/treatment centre

c/o James Illingworth
R&D department
Daisy Building
Castle Hill Hospital
Castle Road
Cottingham
HU16 5JQ
England
United Kingdom

Phone +44 (0)1482 461903
Email james.illingworth@hey.nhs.uk
Website http://www.hey.nhs.uk
ROR logo "ROR" https://ror.org/01b11x021

Funders

Funder type

Government

Seventh Framework Programme ref: FP7-ICT-2007-1, Proposal No 216695
Government organisation / National government
Alternative name(s)
EC Seventh Framework Programm, European Commission Seventh Framework Programme, EU Seventh Framework Programme, European Union Seventh Framework Programme, EU 7th Framework Programme, European Union 7th Framework Programme, Siebten Rahmenprogramm, Séptimo Programa Marco, Septième programme-cadre, Settimo programma quadro, 7th Framework Programme, Seventh EU Framework Programme, FP7

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
HRA research summary 28/06/2023 No No

Editorial Notes

13/06/2019: Contact details updated.
08/08/2016: No publications found in PubMed, verifying study status with principal investigator.